MPLN, through it’s Geneuity Clinical Research Services Division, participated in the instrument performance evaluations that contributed to the FDA approval of the Panther(TM) system for use with the APTIMA 2 Combo assay, particularly testing for the common sexually transmitted infections Chlamydia trachomatis andNeisseria gonorrhoeae. “It is a credit to the scores of talented and dedicated scientists and engineers who made it happen.  We believe that PANTHER will continue that revolution by bringing the power of fully-automated, sample to result capabilities to low- and medium- volume labs.,” said Carl Hull, Gene-Probe’s chairman and chief executive officer.

Leave a Reply